Autologous CAR T-cells targeting Kappa Myeloma Antigen (KMA)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous CAR T-cells targeting Kappa Myeloma Antigen (KMA), covering 2026-04-21 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease [Phase 1]